xeljanz
pfizer europe ma eeig - tofacitinib - artritida, revmatoidní - imunosupresiva - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 a 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.
relosyl 0,050 mg/ml injekční roztok
laboratorios syva, s.a. - gonadoliberin - injekční roztok - gonadotropin-uvolňující hormony - krávy, jalovice
delstrigo
merck sharp & dohme b.v. - doravirine, lamivudin, tenofovir-disoproxyl-fumarát - hiv infekce - antivirotika pro léčbu infekcí hiv, kombinace - delstrigo je indikován k léčbě dospělých infikovaných hiv-1 bez minulosti nebo současnosti důkazy rezistence vůči nnrti třídy, lamivudin, nebo tenofovir. delstrigo is also indicated for the treatment of adolescents aged 12 years and older weighing at least 35 kg who are infected with hiv-1 without past or present evidence of resistance to the nnrti class, lamivudine, or tenofovir and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil.
rabadrop perorální suspenze
bioveta, a.s. - Živé virové vakcíny - perorální suspenze - imunopreparÁt pro canidae - lišky, psíci mývalovití
ervebo
merck sharp & dohme b.v. - rekombinantní vezikulární stomatitis virus (kmen indiana) s odstranění obálky glykoprotein, nahrazuje zaire ebolavirus (kmen kikwit 1995) povrchový glykoprotein - hemoragická horečka, horečka ebola - vakcíny - ervebo is indicated for active immunization of individuals 1 year of age or older to protect against ebola virus disease (evd) caused by zaire ebola virus. použití ervebo by měla být v souladu s oficiálními doporučeními.
tuloxxin 25 mg/ml injekční roztok
krka d.d. novo mesto - tulathromycin - injekční roztok - makrolidy - prasata
ovugel
vetoquinol - triptorelin acetate - hypofýzy a hypotalamické hormony a analogy - pigs (sows for reproduction) - for the synchronisation of ovulation in weaned sows to enable a single fixed-time artificial insemination.
chanimec 10 mg/ml injekční roztok
chanelle pharmaceuticals manufacturing, ltd. - ivermectin - injekční roztok - avermektiny - skot, prasata, ovce
bioestrovet swine 0,0875 mg/ml injekční roztok
vetoquinol s.r.o. - kloprostenol - injekční roztok - prostaglandiny - prasnice, prasničky
huvexxin 25 mg/ml injekční roztok
huvepharma nv - tulathromycin - injekční roztok - makrolidy - prasata